EMPOWER CLINICS INC - EPWCF STOCK NEWS

Empower Clinics has secured over $12 million from warrant exercises, boosting its financial capacity for growth. This follows a previously announced $10.5 million in warrant receipts. The company aims to generate revenue from its KAI Medical Laboratory and new clinic launches over the next year. The recent full Medical Device Establishment Licence (MDEL) allows Empower to sell KAI Saliva COVID-19 tests in Canada. Additionally, three health centers are poised to begin operations in Q2 2021, each expected to generate about $3 million annually. KAI Medical Laboratory also anticipates significant revenue growth.

Empower Clinics Inc. (EPWCF) has announced a partnership with MedX Health Corporation to pilot the DermSecure™ Screening Platform at select locations in Ontario. This initiative aims to enhance teledermatology services, providing virtual assessments within 72 hours to address the shortage of dermatologists in Canada. The pilot is expected to serve around 13,500 patients over four months, with potential expansion across North America depending on the outcomes. The collaboration highlights the need for early melanoma detection amid rising diagnosis and mortality rates in Canada.

Empower Clinics has announced significant growth for its KAI Medical Laboratory in Dallas, TX, which has tripled in size following its acquisition in October 2020. In January and February 2021, KAI LAB achieved record specimen collections, with a 27% growth from January to February. The laboratory's annual revenue run rate now exceeds $10 million. Additionally, an initial soft launch of the KAI Saliva PCR Test resulted in substantial orders, with more expected to meet rising demand. Empower is expanding operational capacity to enhance efficiency and support anticipated growth.

Empower Clinics Inc. (EPWCF) has secured over $10.5 million from warrant exercises, enabling accelerated clinic rollouts and increased processing capacity at Kai Medical. The funds will bolster ongoing revenue growth from its COVID-19 testing services across North America. Empower has also retired long-term debt, strengthening its financial position. CEO Steven McAuley stated that the company is fully funded for its ambitious growth plans in 2021 and continues to achieve its business metrics.

Empower Clinics Inc. (EPWCF) announced the resignation of Dustin Klein, Director & SNR. VP Business Development, effective immediately. Klein is leaving to pursue other interests, as stated by Steven McAuley, Chairman & CEO. A replacement director will be appointed soon. Empower is focused on enhancing its integrated healthcare offerings, which include medical centers and telemedicine. The company is expanding its clinical presence across North America, aiming to deliver long-term value for its shareholders.

Empower Clinics has launched its first three integrated health centers in Ontario, projected to generate between $2,560,000 and $3,600,000 in annual revenue each. With twelve physicians committed and plans for more clinics underway, the company is expanding its national presence. Each center will provide primary and para-medical care, including telemedicine services. Future offerings may include specialized services like dermatology and cardiology. This expansion aligns with Empower's strategy to enhance healthcare accessibility across Canada.

Empower Clinics announced the validation of its KAI Medical Laboratory COVID-19 PCR tests to accurately detect the U.K. (B.1.1.7) and South African (B.1.351) variants. CEO Steven McAuley highlighted the lab's commitment to scientific integrity, indicating this capability enhances their competitive edge in the healthcare market. The World Health Organization emphasized the transmissibility of these variants, underscoring the importance of effective testing. Empower continues to expand its clinical and diagnostic services across North America, aiming for long-term shareholder value.

Empower Clinics (OTCQB: EPWCF) is expanding its KAI Medical Laboratory in Dallas, TX, which has surpassed 1,000 COVID-19 tests in a single day. This milestone marks significant growth since its acquisition in October 2020, when test volumes were under 1,000 monthly. The lab will triple its size to meet projected increases in testing demand across the U.S., Canada, and globally. The expansion, supported by additional logistics and handling staffing, reflects Empower’s commitment to enhancing its integrated healthcare services and responding to rising COVID-19 testing needs.

Empower Clinics Inc. (EPWCF) announced the acquisition of Medical Device Establishment Licence (MDEL) for its KAI Medical COVID-19 Saliva Test kits, allowing them to sell these FDA EUA approved tests in Canada. This partnership with MediPro Canada Inc. is designed to enhance distribution and sales across North America. KAI Saliva offers a convenient, self-administered RT-PCR testing solution for travelers, facilitating compliance with COVID-19 travel requirements. The market demand for such products continues to grow, presenting opportunities for Empower Clinics to expand its integrated healthcare services.